However, regardless of the excellent blockades of purine synthesis on pemetrexed to MTAP-deficient lung adenocarcinoma cell lines in basic research, it is still unclear whether MTAP deficiency could predict the sensitivity of pemetrexed-based treatments in lung adenocarcinoma clinically. The gene discussed is MTAP; the disease is lung adenocarcinoma.